It Takes Courage to be a Pig...Not with PO3, page-35

Regarding an OTC listing, @ozblue posted this on 1/12
“I asked about Nasdaq listing or perhaps OTC but the cost involved just too great. Apparently somnio spent over $1.5m to try this a few years ago without success which is why we ended up with the technology. Down the track it will be looked at, but not on present radar.”

Although Po3 mgt are not looking into it at the moment, it’s probably something Po3 mgt will consider when the next CR is made at likely $10 minimum.

PO3 is not resonating yet to Aussie battlers apart from the few of us. The thread views have more than halved since November from 12k to 5k. And we’re stuck at ridiculously low mcap. This should easily be $250-$300m due to imminence of commercialisation. In the same post of ozblue, OEM’s are using prototypes to do their internal testing and DD. Once news breaks out about a breakthrough OEM agreeement, we probably don’t even need an OTC listing to catapult us into $10-$20 range. It’s a matter of a few more battlers taking a position here, there’s only 2.5m shares not held by the top 22.

The Canadians might join in the next leg up as they seem to be quiet about Po3 in their forum. They might be thinking the same thought as some aussies have which is that they find it high at $5 whilst they fail to realise how ridiculously low the mcap is and how tight the register is. If someone asks questions in the Canadian forum, I’d gladly direct them here for now. It takes 2 months to create an account in their forum .